Indications for Ravulizumab
Ravulizumab is FDA-approved for four distinct indications: paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). 1
FDA-Approved Indications
1. Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Approved for adults and pediatric patients ≥1 month of age 1
- Ravulizumab inhibits terminal complement-mediated intravascular hemolysis by binding complement protein C5, preventing formation of the membrane attack complex (MAC or C5b-9) 1
- The drug achieved complete terminal complement inhibition and normalized serum LDH by week 4 in complement-inhibitor naïve patients 1
- Dosing advantage: Every 8 weeks for adults (vs. eculizumab's 2-week interval), significantly reducing treatment burden 2
2. Atypical Hemolytic Uremic Syndrome (aHUS)
- Approved for adults and pediatric patients ≥1 month of age 1
- Inhibits complement-mediated thrombotic microangiopathy (TMA) 1
- Italian consensus guidelines (2025) confirm ravulizumab has equivalent efficacy to eculizumab with more favorable dosing profile 3
- Critical timing: Treatment should be initiated within 4-8 hours of diagnosis, as delays increase morbidity and mortality 3
- Pregnancy-related aHUS: Women who develop aHUS triggered by pregnancy benefit from C5 inhibitors; treatment should continue for at least 6 months, with discontinuation only after minimum 3 months of stabilized/normalized renal function 3
Important caveat: Patients of Chinese and/or Japanese descent may not respond to C5 inhibitors due to polymorphic variants of the C5 gene (c.2654 G→A, c.2653 C→T) in heterozygous state 3
3. Generalized Myasthenia Gravis (gMG)
- Approved for adults only 1
- Mechanism presumed to involve reduction of terminal complement complex C5b-9 deposition at the neuromuscular junction 1
- Phase 3 CHAMPION MG trial demonstrated significant improvement in QMG scores (MD: -2.91 points), MG-ADL scores (MD: -2.64 points), and quality of life (MG-QoL15r MD: -4.61 points) 4
- 69% of patients achieved clinically meaningful improvement (≥2-point reduction in MG-ADL score) 4
- Modest steroid-sparing effect with corticosteroid dose reduction of 5.98 mg/day 4
4. Neuromyelitis Optica Spectrum Disorder (NMOSD)
- Approved for adults with anti-aquaporin-4 antibody-positive (AQP4+) NMOSD 1
- Mechanism presumed to involve inhibition of aquaporin-4 antibody-induced terminal complement C5b-9 deposition 1
- CHAMPION-NMOSD trial showed 98.6% relapse risk reduction compared to placebo; zero patients on ravulizumab experienced adjudicated relapse during 84 patient-years of treatment 5
- MENACTRIMS 2026 guidelines recommend ravulizumab as a first-line monoclonal antibody option for long-term immunotherapy in NMOSD 6
Emerging Indication (Not Yet FDA-Approved)
IgA Nephropathy
- Phase 3 trial (I CAN) showed ravulizumab resulted in 43.4% greater reduction in proteinuria (24-hour urinary protein-to-creatinine ratio) compared to placebo at week 34 (P<0.001) 7
- This represents a potential future indication, though not currently approved
Critical Safety Requirement Across All Indications
All patients receiving ravulizumab must be vaccinated against meningococcal disease due to increased risk of invasive meningococcal infection from terminal complement blockade 3:
- Quadrivalent A, C, W, Y meningococcal conjugate vaccine
- Serogroup B meningococcal vaccine
- Long-term antimicrobial prophylaxis with penicillin (or macrolides for penicillin-allergic patients) for the duration of treatment 3
Dosing Considerations
Weight-based intravenous dosing with maintenance doses every 4-8 weeks depending on patient weight and indication 1:
- Pediatric patients <20 kg: Every 4 weeks
- Pediatric patients ≥20 to <40 kg: Every 8 weeks
- Patients ≥40 kg: Every 8 weeks
This extended dosing interval compared to eculizumab significantly improves quality of life by reducing infusion center visits, medical appointments, and work/school absences 2.